{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T14:08:40Z","timestamp":1793196520551,"version":"4.5.0"},"reference-count":142,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.bpg.2010.09.004","type":"journal-article","created":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T09:49:35Z","timestamp":1291196975000},"page":"905-921","source":"Crossref","is-referenced-by-count":34,"title":["Short and long-term PPI treatment for GERD. Do we need more-potent anti-secretory drugs?"],"prefix":"10.1016","volume":"24","author":[{"given":"Stanislas","family":"Bruley des Varannes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Coron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Galmiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","article-title":"The montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus","volume":"101","author":"Vakil","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1046\/j.1365-2036.2003.01770.x","article-title":"Quality of life in relation to symptoms in patients with gastro-oesophageal reflux disease \u2013 an analysis based on the ProGERD initiative","volume":"18","author":"Kulig","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib3","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3122\/jabfm.18.5.393","article-title":"Managing gastroesophageal reflux disease in primary care: the patient perspective","volume":"18","author":"Liker","year":"2005","journal-title":"J Am Board Fam Pract"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1542-3565(05)00153-9","article-title":"Prevalence and socioeconomic impact of upper gastrointestinal disorders in the United States: results of the US Upper Gastrointestinal Study","volume":"3","author":"Camilleri","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib5","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1136\/gut.2003.034272","article-title":"Symptom evaluation in reflux disease: workshop background, processes, terminology, recommendations, and discussion outputs","volume":"53","author":"Dent","year":"2004","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib6","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/gast.1997.v112.pm9178669","article-title":"Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis","volume":"112","author":"Chiba","year":"1997","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib7","first-page":"CD003244","article-title":"Medical treatments in the short term management of reflux esophagitis","volume":"18","author":"Khan","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib8","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1053\/j.gastro.2008.12.015","article-title":"Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib9","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1053\/bega.2000.0126","article-title":"Controversies in long-term management of reflux disease","volume":"14","author":"Dent","year":"2000","journal-title":"Bailli\u00e8re\u2019s Best Pract Research Clin Gastroenterol"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1053\/bega.2000.0124","article-title":"Strategies for medical management of reflux disease","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Bailli\u00e8re\u2019s Best Pract Research Clin Gastroenterol"},{"issue":"1\u20132","key":"10.1016\/j.bpg.2010.09.004_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000070393","article-title":"Lansoprazole fast disintegrating tablet: a new formulation for an established proton pump inhibitor","volume":"67","author":"Baldi","year":"2003","journal-title":"Digestion"},{"issue":"10","key":"10.1016\/j.bpg.2010.09.004_bib12","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1046\/j.1365-2036.2000.00829.x","article-title":"Proton pump inhibitors: better acid suppression when taken before a meal than without a meal","volume":"14","author":"Hatlebakk","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib13","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/MCG.0b013e31814b8fc2","article-title":"Esophageal acid exposure on proton pump inhibitors in unselected asymptomatic gastroesophageal reflux disease patients","volume":"42","author":"Grigolon","year":"2008","journal-title":"J Clin Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0016-5085(98)70010-1","article-title":"Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects","volume":"115","author":"Peghini","year":"1998","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib15","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/gast.2002.31876","article-title":"Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough","volume":"122","author":"Fackler","year":"2002","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2008.09.016","article-title":"Proton pump inhibitors in GORD. An overview of their pharmacology, efficacy and safety","volume":"59","author":"Savarino","year":"2009","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.bpg.2010.09.004_bib17","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib18","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00228-004-0804-6","article-title":"Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms","volume":"60","author":"R\u00f6hss","year":"2004","journal-title":"Eur J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib19","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1111\/j.1365-2036.2009.03947.x","article-title":"Effect of proton pump inhibition on the gastric volume: assessed by magnetic resonance imaging","volume":"29","author":"Babaei","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1136\/gut.43.5.603","article-title":"Effect of omeprazole 20 mg twice daily on duodenogastric and gastro-oesophageal bile reflux in barrett\u2019s oesophagus","volume":"43","author":"Marshall","year":"1998","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2036.2004.02271.x","article-title":"Rebound acid hypersecretion after long-term inhibition of gastric acid secretion","volume":"21","author":"Fossmark","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib22","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.gastro.2009.03.058","article-title":"Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy","volume":"137","author":"Reimer","year":"2009","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib23","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/ajg.2010.81","article-title":"Dyspeptic symptoms development after discontinuation of a proton pump inhibitor: a double-blind placebo-controlled trial","volume":"105","author":"Niklasson","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib24","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/ajg.2010.91","article-title":"Editorial: just how \u201cdifficult\u201d is it to withdraw PPI treatment?","volume":"105","author":"Howden","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00228-008-0571-x","article-title":"Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs)","volume":"65","author":"Klotz","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib26","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1365-2036.2000.00835.x","article-title":"Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin pepsinogen I, and chromogranin A in patients with acid related disorders","volume":"14","author":"Sagar","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bpg.2010.09.004_bib27","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/j.1365-2036.2009.03993.x","article-title":"Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy","volume":"29","author":"Lahner","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib28","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/j.1365-2036.2010.04247.x","article-title":"Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving clopidogrel","volume":"31","author":"Kwok","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bpg.2010.09.004_bib29","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1111\/j.1365-2036.2007.03337.x","article-title":"A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving \u2019complete remission\u2019 in gastro-oesophageal reflux disease","volume":"15","author":"Bardhan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","article-title":"Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials","volume":"11","author":"Carlsson","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 4","key":"10.1016\/j.bpg.2010.09.004_bib31","article-title":"A systematic review of symptomatic outcomes used in oesophagitis drug therapy trials","author":"Sharma","year":"2004","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.03235.x","article-title":"Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis","volume":"25","author":"Katz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib33","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1365-2036.2005.02534.x","article-title":"A comparison of esomeprazole and lansoprazole for control of intragastric pH in patients with symptoms of gastro-oesophageal reflux disease","volume":"22","author":"Johnson","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib34","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1365-2036.2004.02085.x","article-title":"The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole","volume":"20","author":"Armstrong","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"16","key":"10.1016\/j.bpg.2010.09.004_bib35","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMcp0804684","article-title":"Clinical practice. Gastroesophageal reflux disease","volume":"359","author":"Kahrilas","year":"2008","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib36","first-page":"CD002095","article-title":"Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease","volume":"19","author":"Van Pinxteren","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib37","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s10620-005-9071-3","article-title":"A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis","volume":"51","author":"Lightdale","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib38","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/s10620-005-9062-4","article-title":"A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis","volume":"51","author":"Schmitt","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.bpg.2010.09.004_bib39","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.dld.2005.04.026","volume":"37","author":"Pace","year":"2005","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib40","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib41","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib42","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2036.2009.04077.x","article-title":"Systematic review: standard and double-dose proton pump inhibitors for the healing of severe erosive oesophagitis \u2013 a mixed treatment comparison of randomized controlled trials","volume":"30","author":"Edwards","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib43","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: proton pump inhibitor failure in gastro-esophageal reflux disease-where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2010.09.004_bib45","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The esomeprazole study investigators","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib46","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/j.1365-2036.2009.03962.x","article-title":"Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis \u2013 results from the EXPO study","volume":"29","author":"Labenz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib47","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S1542-3565(04)00289-7","article-title":"Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment","volume":"2","author":"Vakil","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib48","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1525-1497.2003.20833.x","article-title":"Short-term treatment of gastroesophageal reflux disease","volume":"18","author":"Van Pinxteren","year":"2003","journal-title":"J Gen Intern Med"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib49","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1046\/j.1365-2036.2003.01771.x","article-title":"Esomeprazole resolves chronic heartburn in patients without erosive oesophagitis","volume":"18","author":"Katz","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2010.09.004_bib50","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in non-erosive reflux disease","volume":"2","author":"Dean","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib51","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1046\/j.1365-2036.1997.00185.x","article-title":"Treating the symptoms of gastroesophageal reflux disease. A double-blind comparison of omeprazole and cisapride","volume":"11","author":"Galmiche","year":"1997","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib52","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1572-0241.2002.05769.x","article-title":"Rabeprazole in non erosive gastroesophageal reflux disease: a randomized placebo-controlled trial","volume":"97","author":"Miner","year":"2002","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib53","doi-asserted-by":"crossref","first-page":"69","DOI":"10.2165\/00044011-200323020-00001","article-title":"Lansoprazole and esomeprazole in symptomatic GERD. A double blind, randomised, muticentre trial in 3000 patients confirms comparable symptom relief","volume":"23","author":"Chey","year":"2003","journal-title":"Clin Drug Invest"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib54","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1185\/030079906X100032","article-title":"Does the treatment of gastroesophageal reflux disease meet patients\u2019 needs? A survey-based study","volume":"22","author":"Jones","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib55","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2036.2007.03366.x","article-title":"Overlap of gastro-oesophageal reflux disease and irritable bowel syndrome: prevalence and risk factors in the general population","volume":"26","author":"Jung","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib56","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1365-2036.2010.04339.x","article-title":"Clinical trial: esomeprazole for moderate-to-severe nighttime heartburn and gastro-oesophageal reflux disease-related sleep disturbances","volume":"32","author":"Johnson","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib57","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2036.2004.02079.x","article-title":"Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study","volume":"20","author":"Katz","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib58","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/MOG.0b013e32833ae2be","article-title":"Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors","volume":"26","author":"Hershcovici","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib59","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1572-0241.2006.00829.x","article-title":"Prospective follow-up data from the ProGERD study suggest that GERD is not a categorial disease","volume":"101","author":"Labenz","year":"2006","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib60","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3109\/00365520903314157","article-title":"Is the course of gastroesophageal reflux disease progressive? A 21-year follow-up","volume":"44","author":"Falkenback","year":"2009","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib61","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2008.03804.x","article-title":"Systematic review: persistence and severity in gastro-oesophageal reflux disease","volume":"28","author":"Armstrong","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib62","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2036.1999.00564.x","article-title":"On demand therapy with omeprazole for the long-term management of patients with heartburn without oesophagitis \u2013 placebo-controlled randomized trial","volume":"13","author":"Lind","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2036.2001.00943.x","article-title":"Esomeprazole 20 mg maintains symptom control in endoscopy-negative gastro-oesophageal reflux disease: a controlled trial of on-demand therapy for 6 months","volume":"15","author":"Talley","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib64","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/00042737-200208000-00008","article-title":"Esomeprazole 40 mg and 20 mg is efficacious in the long-term management of patients with endoscopy-negative gastro-oesophageal reflux disease: a placebo-controlled trial of on-demand therapy for 6 months","volume":"14","author":"Talley","year":"2002","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib65","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1097\/00042737-200509000-00009","article-title":"Pantoprazole 20 mg on demand is effective in the long-term management of patients with gastro-oesophageal reflux disease","volume":"17","author":"Kaspari","year":"2005","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2010.09.004_bib66","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2004.01999.x","article-title":"Six month trial of on-demand rabeprazole 10 mg maintains symptom relief in patients with non-erosive reflux disease","volume":"15","author":"Bytzer","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib67","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/j.1365-2036.2005.02637.x","article-title":"Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg","volume":"22","author":"Bigard","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib68","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2036.2009.04092.x","article-title":"Clinical trial: long-term use of proton pump inhibitors in primary care patients \u2013 a cross sectional analysis of 901 patients","volume":"30","author":"Reimer","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib69","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2036.2007.03381.x","article-title":"Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken \u2018on-demand\u2019","volume":"26","author":"Pace","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib70","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","article-title":"Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND study","volume":"20","author":"Tsai","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib71","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/j.1365-2036.2005.02413.x","article-title":"Long-term treatment of gastro-oesophageal reflux disease patients with frequent symptomatic relapses using rabeprazole: on-demand treatment compared with continuous treatment","volume":"21","author":"Bour","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib72","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/00019053-200220040-00005","article-title":"Cost effectiveness of proton pump inhibitors in gastro-oesophageal reflux disease without oesophagitis: comparison of on-demand esomeprazole with conventional omeprazole strategies","volume":"20","author":"Wahlqvist","year":"2002","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.bpg.2010.09.004_bib73","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1016\/S0002-9270(03)00014-5","article-title":"Intermittent and on-demand use of proton pump inhibitors in the management of symptomatic gastroesophageal reflux disease","volume":"98","author":"Bardhan","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"7182","key":"10.1016\/j.bpg.2010.09.004_bib74","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.318.7182.502","article-title":"Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group","volume":"318","author":"Bardhan","year":"1999","journal-title":"Br Med J"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib75","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2036.2003.01446.x","article-title":"A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years","volume":"17","author":"Thjodleifsson","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib76","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1005548318996","article-title":"Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind multicenter, European Trial. The European Rabeprazole Study Group","volume":"45","author":"Thjodleifsson","year":"2000","journal-title":"Dig Dis Sci"},{"issue":"17","key":"10.1016\/j.bpg.2010.09.004_bib77","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1046\/j.1365-2036.2003.01526.x","article-title":"Low-dose or standard-dose proton pump inhibitors for maintenance therapy of gastro-oesophageal reflux disease: a cost-effectiveness analysis","volume":"15","author":"You","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib78","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2036.2003.01464.x","article-title":"Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results","volume":"17","author":"Lauritsen","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib79","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1365-2036.2008.03921.x","article-title":"Health-related quality of life in patients with gastro-oesophageal reflux disease under routine care: 5-year follow-up results of the ProGERD study","volume":"29","author":"Nocon","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib80","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0016-5085(00)70135-1","article-title":"Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa","volume":"118","author":"Klinkenberg-Knol","year":"2000","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib81","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2036.2004.02121.x","article-title":"Prevention of erosive oesophagitis relapse with pantoprazole","volume":"20","author":"Richter","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib82","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1572-0241.2001.03443.x","article-title":"Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety","volume":"96","author":"Johnson","year":"2001","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib83","first-page":"CD003245","article-title":"Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease","volume":"18","author":"Donnellan","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib84","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/gut.2008.148833","article-title":"Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial","volume":"57","author":"Lundell","year":"2008","journal-title":"Gut"},{"issue":"Suppl. 5","key":"10.1016\/j.bpg.2010.09.004_bib85","first-page":"S53","article-title":"Laparoscopic antireflux surgery vs long-term esomeprazole treatment for chronic GERD. Final results after 5 yrs of follow up in the LOTUS study","volume":"138","author":"Galmiche","year":"2010","journal-title":"Gastroenterology"},{"issue":"10","key":"10.1016\/j.bpg.2010.09.004_bib86","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1007\/s11605-008-0645-1","article-title":"Medical or surgical management of GERD patients with Barrett\u2019s esophagus: the LOTUS trial 3-year experience","volume":"12","author":"Attwood","year":"2008","journal-title":"J Gastrointest Surg"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib87","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000210097","article-title":"Epidemiology of the complications of gastroesophageal reflux disease","volume":"27","author":"Belhocine","year":"2009","journal-title":"Dig Dis"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib88","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/j.1365-2036.2009.03990.x","article-title":"Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis \u2013 results from the maintenance phase of the EXPO study","volume":"29","author":"Labenz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib89","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/j.1365-2036.2006.03084.x","article-title":"Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial","volume":"24","author":"Bj\u00f6rnsson","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2036.2007.03248.x","article-title":"Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical center","volume":"25","author":"Cot\u00e9","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.bpg.2010.09.004_bib91","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.cgh.2009.03.006","article-title":"What makes individuals with gastroesophageal reflux disease dissatisfied with their treatment?","volume":"7","author":"Bytzer","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"443","key":"10.1016\/j.bpg.2010.09.004_bib92","first-page":"463","article-title":"Factors influencing compliance in long-term proton pump inhibitor therapy in general practice","volume":"49","author":"Hungin","year":"1999","journal-title":"Br J Gen Pract"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib93","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/00365520212499","article-title":"On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole","volume":"37","author":"Johnsson","year":"2002","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib94","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/MOG.0b013e32833adc8d","article-title":"Extraesophageal manifestations of gastroesophageal reflux disease: real or imagined?","volume":"26","author":"Moore","year":"2010","journal-title":"Curr Opin Gastroenterol"},{"issue":"15","key":"10.1016\/j.bpg.2010.09.004_bib95","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa0806290","article-title":"Efficacy of esomeprazole for treatment of poorly controlled asthma","volume":"360","author":"Mastronarde","year":"2009","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib96","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/01.mlg.0000192173.00498.ba","article-title":"Treatment of chronic posterior laryngitis with esomeprazole","volume":"116","author":"Vaezi","year":"2006","journal-title":"Laryngoscope"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib97","first-page":"CD004823","article-title":"Review: insufficient evidence exists on the effectiveness of proton pump inhibitors for adults with prolonged non-specific cough associated with gastro-oesophageal reflux","author":"Chang","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib98","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1365-2036.2008.03611.x","article-title":"Review article: respiratory manifestations of gastro-oesophageal reflux disease","volume":"27","author":"Galmiche","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.bpg.2010.09.004_bib99","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1164\/rccm.200507-1167OC","article-title":"Effects of esomeprazole 40 mg twice daily on asthma: a randomised placebo-controlled trial","volume":"173","author":"Kiljander","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib100","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1111\/j.1572-0241.2005.41657.x","article-title":"Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a meta-analysis","volume":"100","author":"Cremonini","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib101","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1001\/archinte.165.11.1222","article-title":"Is proton pump inhibitor testing an effective approach to diagnose gastroesophageal reflux disease in patients with noncardiac chest pain? A meta-analysis","volume":"165","author":"Wang","year":"2005","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.bpg.2010.09.004_bib102","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1365-2036.2009.03981.x","article-title":"Clinical course of laryngo-respiratory symptoms in gastro-oesophageal reflux disease during routine care \u2013 a 5-year follow-up","volume":"29","author":"Jaspersen","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib103","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/gut.2009.194795","article-title":"Helicobacter pylori represses proton pump expression and inhibits acid secretion in human gastric mucosa","volume":"59","author":"Saha","year":"2010","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib104","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1046\/j.1365-2036.2003.01488.x","article-title":"Eradication of Helicobacter pylori increases nocturnal intragastric acidity during dosing with rabeprazole, omeprazole, lansoprazole and placebo","volume":"17","author":"Williams","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib105","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/gut.2005.066464","article-title":"Helicobacter pylori eradication induces marked increase in H+\/K+ -adenosine triphosphatase expression without altering parietal cell number in human gastric mucosa","volume":"55","author":"Osawa","year":"2006","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib106","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0016-5085(99)70544-5","article-title":"Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole","volume":"117","author":"Holtmann","year":"1999","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib107","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1365-2036.2004.02096.x","article-title":"Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?","volume":"20","author":"Wit","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.bpg.2010.09.004_bib108","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.3748\/wjg.v16.i19.2323","article-title":"Safety of the long-term use of proton pump inhibitors","volume":"21","author":"Thomson","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib109","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/gut.2005.071779","article-title":"Mechanisms of increased acid secretion after eradication of Helicobacter pylori infection","volume":"55","author":"El-Omar","year":"2006","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/j.1365-2036.2006.02983.x","article-title":"Predictors of treatment response in patients with non-erosive reflux disease","volume":"15","author":"Talley","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. II","key":"10.1016\/j.bpg.2010.09.004_bib111","first-page":"A279","article-title":"Is BMI associated with pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in GERD patients?","volume":"58","author":"Bruley des Varannes","year":"2009","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib112","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1111\/j.1572-0241.2008.01979.x","article-title":"Body mass index can determine the healing of reflux esophagitis with Los Angeles Grades C and D by esomeprazole","volume":"103","author":"Sheu","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib113","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.bpg.2009.11.004","article-title":"Adverse effects of proton pump inhibitors","volume":"24","author":"Lodato","year":"2010","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"7634","key":"10.1016\/j.bpg.2010.09.004_bib114","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/bmj.39406.449456.BE","article-title":"Overprescribing proton pump inhibitors","volume":"336","author":"Forgacs","year":"2008","journal-title":"Br Med J"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib115","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/ajg.2009.631","article-title":"Long-term outcome of microscopic esophagitis in chronic GERD patients treated with esomeprazole or laparoscopic antireflux surgery in the LOTUS trial","volume":"105","author":"Fiocca","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib116","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/j.1365-2036.2006.03127.x","article-title":"Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy","volume":"24","author":"Jalving","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.bpg.2010.09.004_bib117","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1001\/jama.296.24.2947","article-title":"Long-term proton pump inhibitor therapy and risk of hip fracture","volume":"296","author":"Yang","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib118","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1053\/j.gastro.2009.12.007","article-title":"Hip fracture risk in patients with a diagnosis of pernicious anemia","volume":"138","author":"Merriman","year":"2010","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib119","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/archinternmed.2010.94","article-title":"Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women Results women\u2019s health initiative","volume":"170","author":"Gray","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.bpg.2010.09.004_bib120","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1046\/j.1365-2036.1999.00616.x","article-title":"Atrophic gastritis during long-term omeprazole therapy affects serum vitamin B12 levels","volume":"13","author":"Schenk","year":"1999","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib121","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2036.2008.03924.x","article-title":"Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting","volume":"29","author":"Dalton","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib122","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1001\/archinternmed.2010.89","article-title":"Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection","volume":"170","author":"Howell","year":"2010","journal-title":"Arch Intern Med"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib123","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/archinternmed.2010.73","article-title":"Proton pump inhibitors and risk for recurrent Clostridium difficile infection","volume":"170","author":"Linsky","year":"2010","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.bpg.2010.09.004_bib124","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1136\/gut.52.7.942","article-title":"Mortality study of 18 000 patients treated with omeprazole","volume":"52","author":"Bateman","year":"2003","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.bpg.2010.09.004_bib125","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2036.2005.02306.x","article-title":"The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study","volume":"21","author":"Diav-Citrin","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib126","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000235953","article-title":"Management of reflux symptoms with over-the-counter proton pump inhibitors: issues and proposed guidelines","volume":"80","author":"Haag","year":"2009","journal-title":"Digestion"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2010.09.004_bib127","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000200917","article-title":"Appropriate acid suppression for the management of gastro-oesophageal reflux disease","volume":"51","author":"Bell","year":"1992","journal-title":"Digestion"},{"issue":"Suppl. 1","key":"10.1016\/j.bpg.2010.09.004_bib128","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1365-2036.2006.02801.x","article-title":"Review article: intragastric and oesophageal pH monitoring in patients with gastro-oesophageal reflux disease","volume":"23","author":"Katz","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib129","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S1542-3565(05)00023-6","article-title":"Early heartburn relief with proton pump inhibitors: a systematic review and meta-analysis of clinical trials","volume":"3","author":"McQuaid","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib130","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1572-0241.2005.41210.x","article-title":"The role of esophageal pH monitoring in symptomatic patients on PPI therapy","volume":"100","author":"Charbel","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.bpg.2010.09.004_bib131","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2036.2009.03984.x","article-title":"Review article: dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 3","key":"10.1016\/j.bpg.2010.09.004_bib132","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2036.2005.02709.x","article-title":"Review article: immediate-release proton pump inhibitor therapy \u2013 potential advantages","volume":"22","author":"Howden","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.bpg.2010.09.004_bib133","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1365-2036.2005.02513.x","article-title":"Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease","volume":"15","author":"Castell","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.bpg.2010.09.004_bib134","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2036.2006.03191.x","article-title":"Comparison of the effects of immediate release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms","volume":"25","author":"Katz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib135","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2036.2004.01893.x","article-title":"Tenatoprazole, a novel proton pump inhibitor with a prolonged plasma half-life: effects on intragastric pH and comparison with esomeprazole in healthy volunteers","volume":"19","author":"Galmiche","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.bpg.2010.09.004_bib136","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1365-2036.2005.02381.x","article-title":"A comparative study of the early effects of tenatoprazole 40 mg and esomeprazole 40 mg on intragastric pH in healthy volunteers","volume":"21","author":"Galmiche","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib137","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2036.2009.04219.x","article-title":"The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects","volume":"31","author":"Hunt","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.bpg.2010.09.004_bib138","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOG.0b013e32832c1504","article-title":"Evolving issues in the management of reflux disease","volume":"25","author":"Yuan","year":"2009","journal-title":"Curr Opin Gastroenterol"},{"issue":"12","key":"10.1016\/j.bpg.2010.09.004_bib139","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2007.08.014","article-title":"A randomized, comparative study of three doses of AZD0865 and esomeprazole for healing of reflux esophagitis","volume":"5","author":"Kahrilas","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.bpg.2010.09.004_bib140","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1572-0241.2007.01544.x","article-title":"A randomized, comparative trial of a potassium-competitive acid blocker (AZD0865) and esomeprazole for the treatment of patients with nonerosive reflux disease","volume":"103","author":"Dent","year":"2008","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.bpg.2010.09.004_bib141","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1742-7843.2005.pto_273.x","article-title":"Pharmacological targets in gastro-oesophageal reflux disease","volume":"97","author":"Piche","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1\u20132","key":"10.1016\/j.bpg.2010.09.004_bib142","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000091298","article-title":"Acid suppression therapy: where do we go from here?","volume":"24","author":"Scarpignato","year":"2006","journal-title":"Dig Dis"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691810001137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691810001137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T17:20:47Z","timestamp":1711992047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691810001137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":142,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S1521691810001137"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2010.09.004","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}